Gene Therapy Partnering Deals & Agreements By Healthcare Companies Analyzed in New Research Report at ReportsnReports.com

Dallas, Texas (PRWEB) July 07, 2013

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the world's leading healthcare companies:

Trends in gene therapy partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Gene therapy partnering contract documents
Top gene therapy deals by value

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals (http://www.reportsnreports.com/reports/262461-gene-therapy-partnering-terms-and-agreements.html). The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene therapy technologies and products.

Key Benefits:
Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of gene therapy deal trends since 2007
Access to headline, upfront, milestone and royalty data
Analysis of the structure of gene therapy agreements with numerous real life case studies
Comprehensive access to over 100 actual gene therapy contracts entered into by the world’s biopharma companies
Detailed access to actual gene therapy contracts enter into by the leading fifty bigpharma
Insight into the terms included in gene therapy agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=262461. Alternatively can get DISCOUNT @ http://www.reportsnreports.com/contacts/discount.aspx?name=262461.

Report Scope:
Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.
Gene Therapy Partnering Terms and Agreements includes:
Trends in gene therapy dealmaking in the biopharma industry since 2007
Analysis of gene therapy deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life gene therapy deals
Access to over 300 gene therapy contract documents
The leading antibody deals by value since 2007
Most active gene therapy dealmakers since 2007
The leading gene therapy partnering resources

In Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Explore more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/.

About US:
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets.

PDF Print